Initial Findings from the First Four Patients Enrolled in OTC-HOPE Clinical Trial: No Hyperammonemic Events in First Participant to Complete 24-week Study
https://iecure.com/wp-content/uploads/ICIEM-poster_web.pdf
https://iecure.com/wp-content/uploads/ICIEM-poster_web.pdf
https://iecure.com/wp-content/uploads/iECURE_ASGCT_Poster-852_Final.pdf